



Food and Drug Administration  
Rockville MD 20857

Re: Strattera  
Docket No. 03E-0261

The Honorable Jon Dudas  
Acting Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office  
Box Pat. Ext.  
P.O. Box 1450  
Alexandria, VA 22313-1450

~~NOV 23 2004~~

Dear Acting Director Dudas:

This is in regard to the patent term extension application for U.S. Patent No. 5,658,590, filed by Eli Lilly & Company under 35 U.S.C. § 156. The patent claims Strattera (atomoxetine hydrochloride), NDA 21-411.

In the December 3, 2003, issue of the Federal Register (68 Fed. Reg. 67678), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before June 1, 2004, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Charles E. Cohen  
Eli Lilly & Company  
Patent Division/CEC  
Lilly Corporate Center  
Indianapolis, IN 46285

03E-0261

LET S